

Neuralstem, Inc.  
Form 8-K  
August 05, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): August 5, 2014 (August 4, 2014)**

**Neuralstem, Inc.**

**(Exact name of registrant as specified in Charter)**

|   |                              |  |
|---|------------------------------|--|
| <b>Delaware</b>   | <b>000-1357459</b>           | <b>52-2007292</b>                        |
| <b>(State or other jurisdiction of<br/>incorporation or organization)</b> | <b>(Commission File No.)</b> | <b>(IRS Employee Identification No.)</b> |

**20271 Goldenrod Lane, 2<sup>nd</sup> Floor**

**Germantown, Maryland 20876**

**(Address of Principal Executive Offices)**

**(301) 366-4960**

**(Issuer Telephone number)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On August 4, 2014, Neuralstem, Inc. (“Company”) announced that the final patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). A copy of the press release is attached to this report as Exhibit 99.01.

**Item 9.01 Financial Statement and Exhibits.**

| <b>Exhibit<br/>Number</b> | <b>Description</b>                 |
|---------------------------|------------------------------------|
| 99.01                     | Press Release Dated August 4, 2014 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Issuer has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

NEURALSTEM, INC

By: /s/ I. Richard Garr  
I. Richard Garr  
Chief Executive Officer

Dated: August 5, 2014

**INDEX OF EXHIBITS**

| <b>Exhibit<br/>Number</b> | <b>Description</b> |
|---------------------------|--------------------|
|---------------------------|--------------------|

|       |                                    |
|-------|------------------------------------|
| 99.01 | Press Release Dated August 4, 2014 |
|-------|------------------------------------|